Dr. Porcu Discusses CTCL

3 Tampilan
administrator
administrator
08/09/23

Pierluigi Porcu, MD, associate professor of internal medicine, Division of Hematology, Department of Internal Medicine, Wexner Medical Center, The Ohio State University, discusses cutaneous T cell lymphoma (CTCL).

  • Kategori

Menampilkan lebih banyak
0 Komentar Sortir dengan

    Tidak ada komentar yang ditemukan

    Komentar Facebook

    Berikutnya

    Dr. Goldberg Discusses the Diagnosis of Mesothelioma
    00:01:21
    Dr. Goldberg Discusses the Diagnosis of Mesothelioma
    administrator
    1 Tampilan
    Dr. Tresley discusses Skin Cancer Eyelid Reconstruction
    00:01:28
    Dr. Tresley discusses Skin Cancer Eyelid Reconstruction
    administrator
    2 Tampilan
    Dr. Cohen Discusses Surgery in Early Stage Ovarian Cancer
    00:02:06
    Dr. Cohen Discusses Surgery in Early Stage Ovarian Cancer
    administrator
    1 Tampilan
    Neil Oliver discusses a rare cancer, Ewing Sarcoma, with the sister of one of its victims
    00:07:00
    Neil Oliver discusses a rare cancer, Ewing Sarcoma, with the sister of one of its victims
    administrator
    1 Tampilan
    Dr. Mitchel Goldman Discusses Stuart Scott's Rare Cancer
    00:04:30
    Dr. Mitchel Goldman Discusses Stuart Scott's Rare Cancer
    administrator
    3 Tampilan
    Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
    00:03:06
    Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
    administrator
    3 Tampilan
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    00:02:51
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    administrator
    2 Tampilan
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    00:02:30
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    administrator
    3 Tampilan
    The CTCL diagnosis journey
    00:00:20
    The CTCL diagnosis journey
    administrator
    6 Tampilan
    Unmet needs for late-stage CTCL
    00:01:10
    Unmet needs for late-stage CTCL
    administrator
    3 Tampilan
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    00:01:16
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    administrator
    3 Tampilan
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    00:01:35
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    administrator
    4 Tampilan
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    00:08:49
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    administrator
    10 Tampilan
    Pre-clinical activity of tipifarnib in CTCL
    00:02:12
    Pre-clinical activity of tipifarnib in CTCL
    administrator
    5 Tampilan
    Cerdulatinib yields 'encouraging' results in CTCL, PTCL
    00:04:47
    Cerdulatinib yields 'encouraging' results in CTCL, PTCL
    administrator
    4 Tampilan
    CTCL 06 2017
    02:28:08
    CTCL 06 2017
    administrator
    2 Tampilan
    Brentuximab vedotin for CTCL
    00:02:30
    Brentuximab vedotin for CTCL
    administrator
    2 Tampilan
    Clonal evolution in patients with CTCL
    00:02:24
    Clonal evolution in patients with CTCL
    administrator
    3 Tampilan
    RESMAIN: HDAC inhibitor resminostat for CTCL
    00:01:23
    RESMAIN: HDAC inhibitor resminostat for CTCL
    administrator
    2 Tampilan